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Background: To determine the feasibility of combining concurrent
carboplatin/paclitaxel and thoracic radiotherapy (TRT) for com-
pletely resected stage II and IIIA non-small cell lung cancer.
Methods: Eligibility stipulated gross total resections with involved
lymph nodes (N1 or N2), pathologic stage II or IIIA non-small cell
lung cancer. TRT consisted of 50.4 Gy in 28 fractions with a boost
of 10.8 Gy for extranodal extension (ENE) or 16.2 Gy for involved
surgical margins. Chemotherapy was administered every 3 weeks:
carboplatin (area under the curve of 5) and paclitaxel (175 mg/m2)
during TRT for two cycles, with doses increased to an area under
the curve of 7.5 and 225 mg/m2, respectively, for two cycles after
TRT. Cox multivariate regression analysis was used to confirm
independent predictors of outcome among clinical and treatment-
related factors: age, T stage, N stage, presence of ENE, presence
of involved surgical margins, histopathology.
Results: Between April 1997 and March 2001, 42 patients were
enrolled. Two patients were deemed ineligible due to having T4
disease, leaving 40 patients for analysis. Ninety-two percent (37/40)
of patients had T1 or T2 disease; 60% (24/40) had N2 disease. Nine
patients (22.5%) had ENE and 15% (six patients) had involved
surgical margins. At a median follow up of 37 months (range,
3–103; median, 68 months for living patients), the 2- and 5-year
Kaplan–Meier estimates of local regional control, freedom from
distant metastasis, freedom from brain metastasis, and overall sur-
vival were 92% and 88%, 77% and 59%, 87% and 71% and 72%
and 44%, respectively. Fourteen patients developed distant metas-
tasis as the initial site of failure, eight of whom had brain metastasis.
Brain metastasis was the only site of failure in four of the eight
patients. Multivariate regression analysis demonstrated that the only
independent predictor of overall survival was histology (p  0.02).
Patients with adenocarcinoma had a 5-year overall survival of 28%
versus 68% for all other cell types. There were no independent
predictors of distant metastases or brain metastases on multivariate
regression analysis. Treatment was tolerated reasonably well: 92%
of patients (37/40) received the planned doses of TRT; 67% of
patients (27/40) received all four cycles of chemotherapy. Five
patients developed grade 3 esophagitis, and three patients experi-
enced grade 3 pneumonitis. Two patients experienced grade 5
toxicity. One was treatment related due to a patient who developed
grade 3 esophagitis who developed an aspiration pneumonia that
progressed to acute respiratory distress syndrome.
Conclusions: Our results support the Radiation Therapy Oncology
Group 97-05 findings and suggest that with new and better tolerated
chemotherapy regimens the strategy of concurrent TRT and chemo-
therapy after completely resected stage II and IIIA non-small cell
lung cancer should be further explored.
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Non-small cell lung cancer (NSCLC) represents the mostcommon cause of cancer deaths in the United States. Of
all patients who present with NSCLC, approximately 30% are
able to undergo complete resections.1 Mountain2 has shown
that patients with pathologic stage I NSCLC have 5-year
survival rates in the range of 60% to 70%. However, patients
with pathologic stage II or IIIA disease have substantially
lower 5-year survival rates.3–5
Although this approach is feasible, deficiencies in these
early trials have included overtreating patients with early
stage disease and the use of suboptimal radiation techniques,
which probably led to an increased risk of death related to
radiation-induced morbidity. In fact, a meta-analysis evalu-
ating the role of postoperative radiotherapy demonstrated a
survival detriment with the addition of radiation.6 This anal-
ysis has been criticized for many reasons. For example, the
largest series in this meta-analysis demonstrated a 30% risk
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of death due to intercurrent disease for patients treated with
radiotherapy.7 This trial exemplifies the differences from
modern techniques whereby patients were treated with sub-
optimal techniques such as lateral fields, the use of cobalt 60,
and large fraction size (2 Gy per fraction). This study
demonstrated an increased risk of dying from intercurrent
disease with increasing dose per fraction. Modern techniques
seem to alleviate these concerns.8 This study was too small to
estimate the risk of intercurrent disease.
Over the past several years, large randomized trials
have shown survival benefits with the addition of chemother-
apy for surgically treated patients with lung cancer.9–12 This
had a major impact on patterns of care with an emphasis on
chemotherapy as the major adjuvant therapy after surgery.
When hilar or mediastinal lymph nodes are involved, the risk
of local recurrence ranges from 9 to 54.3,13–18 In light of these
large randomized series, where is the benefit (i.e., decreasing
distant metastases, decreasing local/regional failures or
both?). Do we need radiation therapy for local control any-
more? The Cancer and Leukemia Group B protocol 9633
included only stage IB patients.10 The Japan Lung Cancer
Group trial included only stage I patients as well.19 The
JBR.10 trial included stage IB and II patients, although
excluded patients with tracheobronchial lymph nodes (station
10 or proximal hilar nodes); therefore, both of these trials
excluded patients at a significant local recurrence. There are
three recent studies that have evaluated chemotherapy after
surgery in a similar patient population.9,11,20 All three studies
allowed patients to receive postoperative radiotherapy at the
preference of the treating physician. Approximately one third
of patients with N1 disease and two thirds of patients with N2
disease received radiotherapy to the mediastinum. Interest-
ingly, the benefits of adjuvant chemotherapy observed were
seen in the subgroups of patients more often treated with
radiotherapy.20,21 Unfortunately, none of these larger studies
adequately elaborate on locoregional disease control. One
study that sheds light on patients with pathologic N2 disease
was a large multicenter phase II study that tested cisplatin and
docetaxel before surgery.22 Seventy-five of 90 patients had
surgery. Radiation therapy was only offered to patients with
involved surgical margins or involvement of the highest
mediastinal lymph node (received by 33 patients). The local
recurrence rate at the time of first failure was seen in 22 of the
75 patients, and they described that with longer follow-up
local failures were seen in 45 of the patients. All in all,
chemotherapy likely decreases distant metastasis but has less
of an impact on local control as seen in other disease sites,
whereas radiotherapy can have a significant impact on locore-
gional control, but requires good systemic control to translate
into a survival benefit. For example, in the postmastectomy
setting in breast cancer, radiotherapy improved local regional
control but had no impact on survival until better chemother-
apy was available to control distant metastasis.23
When this study was first developed, the results of
Eastern Cooperative Oncology Group (ECOG) 3590 trial
were not available.24 ECOG 3590 was a phase III trial in
completely resected stage II and IIIA NSCLC, where patients
were randomized to postoperative radiation therapy (PORT)
versus PORT plus four cycles of cisplatin and etoposide.
Carboplatin and paclitaxel were new and promising with
similar efficacy and less toxicity than cisplatin-based regi-
mens as employed in ECOG 3590. This phase II study was
developed as a more tolerable adjuvant treatment compared
with the concurrent chemoradiotherapy arm in ECOG 3590
and therefore more effective treatment.
This study describes a prospective phase II trial that
combined modern radiotherapy based on computed tomogra-
phy (CT) treatment planning combined with systemic doses
of carboplatin and paclitaxel administered concurrently and
adjuvantly after surgical resection at the Fox Chase Cancer
Center and its network affiliates.
PATIENTS AND METHODS
The trial was initiated in 1997 and was conducted at
Fox Chase Cancer Center and several of its network affiliates.
All patients on this institutional review board–approved trial
underwent informed consent. Patients were considered eligi-
ble for this protocol if they had pathologic stage II or IIIA
(T1, T2, T3, and N1-N2) NSCLC. Complete gross resection
of the tumor was required. Sublobar resections were not
allowed. Patients with positive margins were included, but
were mandated to receive a higher dose of radiation. Regis-
tration was performed before 8 weeks after definitive surgery.
All surgeons were encouraged but not required to perform a
complete mediastinal nodal dissection or sampling. Complete
lymph node dissection involves removing all lymph nodes at
the anatomically defined level. Lymph node sampling neces-
sitates opening the pleura and removing representative tissue
from each lymph node level. For this study, a complete
mediastinal dissection or sampling includes the following
nodal levels: Levels 2 and 4, level 8, levels 5 and 6 (in all
patients when the primary lesion is located in the left lung),
level 7, level 9, level 10. All ipsilateral lymph node at levels
11 to 13 should be removed en bloc with the primary surgical
specimen. Patients had to have a good performance status
(ECOG 0 or 1), adequate postsurgical pulmonary function
(forced expiratory volume at 1 second 1 liter), adequate
end-organ function (absolute neutrophil count 2000, plate-
lets 10,000, bilirubin 1.5, and creatinine 2.0) and be at
least 18 years of age. All patients underwent a complete
history and physical examination and staging workup includ-
ing a CT scan of the thorax and upper abdomen with contrast,
bone scan, and CT or magnetic resonance imaging of the
brain. Positron emission tomography scans were not per-
formed for any patient in this study. Patients were considered
ineligible if they had previous thoracic radiotherapy or pre-
vious chemotherapy (for this diagnosis). Patients were not
allowed to have had a previous or concurrent invasive ma-
lignancy within 3 years of enrollment. Patients with stage I,
IIIB, or IV were specifically excluded.
Radiation therapy was initiated between 4 and 8 weeks
after surgery. All patients were treated with isocentric equip-
ment with a minimum SSD of 80 cm using megavoltage
equipment with photon energies of 4 to 12 MV. The desired
target was the ipsilateral hilar and mediastinal lymph nodes.
The contralateral hilum or supraclavicular fossa was not
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included on a routine basis. The field borders were based on
anatomic landmarks, although a postoperative CT scan was
performed to document postsurgical anatomic changes. In
general, the superior border was at the lung apex (typically
C5). The inferior border was 5 cm below the carina for upper
and middle lobe tumors and 8 cm below the carina for lower
lobe tumors or when there was histologic subcarinal lymph
node involvement. The ipsilateral border was 2 cm beyond
the tracheal edge encompassing the ipsilateral hilum with a
2-cm margin. The contralateral border was defined as 2 cm
lateral to the edge of the trachea. These volumes were treated
to 5040 cGy at 180 cGy per fraction 5 days per week. Initially
using an anteroposterior-postanterior technique to approxi-
mately 40 Gy followed by oblique fields keeping the total
dose to the spinal cord to less than 45 Gy. Patients in whom
extranodal extension was documented pathologically, re-
ceived an additional 1080 cGy in six fractions to these nodal
stations (total dose 6120 cGy). Patients with involved surgi-
cal margins received an additional 1620 cGy in nine fractions
(total dose 6660 cGy). Inhomogeneity corrections were not
used. One investigator (B.M.) reviewed all the radiation
simulation fields and isodose distributions at the central axis.
Chemotherapy was administered concurrently on days
1 and 22 of radiation with carboplatin (area under the curve
of 5) and paclitaxel (175 mg/m2). Two additional cycles were
administered after radiation on days 43 and 64 with carbo-
platin (area under the curve of 7.5) and paclitaxel (225
mg/m2). The higher doses of carboplatin and paclitaxel were
chosen to have an impact on systemic disease. Routine
antiemetics were given using ondansetron and lorazepam.
Dose modifications (20%) were made if the platelets dropped
below 25,000 for more than 5 days or if the subsequent
course of chemotherapy was delayed more than 7 days.
Granulocyte colony–stimulating factor was not administered
during radiation. A dose reduction of 25% for cycle 2 was
performed for nonhematologic grade 3 and 4 toxicities, ex-
cluding nausea, vomiting, and alopecia.
All patients were recommended to receive an iced
carafate slurry (1 g of elixir dissolved in ½ cup of ice cold
water) 15 minutes before and immediately after daily radia-
tion treatments. Because the main acute side effect of con-
current therapy is esophagitis, hypothermia using the iced
carafate was used to decrease this morbidity. In addition,
patients were given instructions to avoid drinking hot liquids
during radiation.
Follow-up examinations consisted of weekly visits during
radiation and before each dose of chemotherapy. Esophageal
quality of life was measured at every office visit until 1½ years
after the completion of therapy. After surgery, patients under-
went a follow-up CT scan of the thorax and upper abdomen
every 6 months for 3½ years and annually thereafter.
Statistical Consideration
The primary endpoints were to determine (1) the fea-
sibility of combining radiation therapy and carboplatin/pac-
litaxel and (2) the local control rates and survival by using
this approach. The secondary endpoints were looking at
toxicity and efficacy of hypothermia in reducing esophagitis
and to describe the patterns of failure. Thirty-five patients
were needed assuming the 2-year survival with this new
treatment would increase to 65% from 40%, based on the
Lung Cancer Study Group to test the null hypothesis: p 
0.40 against the alternative hypothesis: p  0.65 with 11%
significance and 96% power. Due to an anticipated dropout
rate of 20% in this population, 42 patients were accrued.
Actuarial curves were generated using Kaplan-Meier (KM)
methodology, whereas multivariate analysis (MVA) was per-
formed using Wilcoxon tests. MVA was performed to de-
termine independent predictors of outcome for overall
survival (OS), distant metastasis (DM), and brain metas-
tasis (BM). The covariates analyzed included age (contin-
uous), gender, T stage, N stage, presence of extranodal
extension, presence of positive margins, and histology
(adenocarcinoma versus other).
RESULTS
Between April 1997 and March 2000, 42 patients were
enrolled. Two patients were deemed ineligible due to T4
disease, leaving 40 patients eligible for the analysis. Patient
characteristics are described in Table 1. Median follow-up is
37 months (range, 3–103) for all patients and 68 months for
the living patients. Twenty-five patients had T2 disease, 12
patients had T1 disease, and three patients had T3 disease.
The majority of the patients had N2 disease (60%). Extran-
odal extension was reported in nine patients, and six patients
had involved surgical margins.
Thirty-one patients underwent a lobectomy, and nine
patients underwent a pneumonectomy. Every patient under-
went a sampling of the mediastinum, although only 19 were
TABLE 1. Patient Characteristics
Median age, y 66 (range, 45–75)
Gender 19 males, 21 females
T stage
T1 12 (30%)
T2 25 (62.5%)
T3 3 (7.5%)
N stage
N1 16 (40%)
N2 24 (60%)
Overall stage
II 14 (35%)
IIIA 26 (65%)
Involved surgical margins 6 (15%)
Extranodal extension present 9 (22.5%)
Pathology
Squamous 10 (25%)
Adenocarcinoma 24 (60%)
Large cell 3 (7.5%)
Mixed adenosquamous 3 (7.5%)
Radiation dose 5040 (540–6660)
Cycles of chemotherapy
1 1 (2.5%)
2 6 (15%)
3 6 (15%)
4 27 (67.5%)
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considered to be complete. No patient underwent a complete
dissection.
Radiation was given within 5% of that described in the
protocol in 92% of patients. The median radiation dose was
50.4 Gy (range, 5.4–66.6 Gy). Two thirds of patients re-
ceived four cycles of chemotherapy and nearly 83% received
three or four cycles.
Local Regional Control
Only four patients developed either a local (two pa-
tients) or regional failure (three patients) for a KM estimate of
local regional control of 91 and 88% at 2 and 5 years (Figure
1). Three of four patients who developed local failure also
had DM at the time of first failure.
Distant Metastasis
Fourteen patients developed DM, of whom eight had
BM with or without other sites of involvement. Table 2
illustrates the patient characteristics that may have an impact
on local regional control, DM, and BM. Four of eight patients
with BM had the brain as the only site of failure. The KM
estimates of freedom from DM (FFDM) at 2 and 5 years was
77% and 59%, respectively. On MVA, there were no inde-
pendent predictors of DM. The KM estimates of FFBM at 2
and 5 years was 86% and 71%, respectively. On MVA, there
were no independent predictors of FFBM, although there was an
interesting trend specifically looking at age. In fact, no patients
older than 60 years of age developed BM (23 patients). Figure 2
illustrates this issue in the development of BM.
Overall Survival
The KM estimates of OS at 2 and 5 years were 72%
and 44%, respectively. MVA on OS demonstrated that
histology was the only independent predictor of OS (p 
0.02). Patients with adenocarcinoma had a 5-year OS
survival of 28% in comparison with 68% for other cell
types, as illustrated in Figure 3. As illustrated in Table 2,
it appears that patients with adenocarcinomas appear to
drive this impact on survival by an increased risk ofFIGURE 1. Kaplan–Meier estimate of local regional control.
TABLE 2. Treatment Failures as a Function of Clinical and
Treatment-related Parameters
% with DM % BM % LRF
T stage
T1 3/12 (25%) 1/12 (8%) 0/12 (0%)
T2 9/25 (36%) 5/25 (20%) 3/25 (12%)
T3 2/3 (67%) 2/3 (67%) 1/3 (33%)
N stage
N1 2/16 (12.5%) 2/16 (12.5%) 3/16 (18.8%)
N2 12/24 (50%) 6/24 (25%) 1/24 (4%)
Surgical margins
Involved 3/6 (50%) 3/6 (50%) 1/6 (16.7%)
Not involved 10/34 (29.4%) 5/34 (14.7%) 3/34 (8.8%)
ECE
Present 1/9 (11%) 0/9 (0%) 1/9 (11%)
Absent 13/31 (41.9%) 8/31 (25.8%) 3/31 (9.7%)
Pathology
Squamous 0/10 (0%) 0/10 (0%) 0/10 (0%)
Adenocarcinoma 14/24 (58%) 8/24 (33%) 3/24 (12.5%)
Large cell carcinoma 0/3 (0%) 0/3 (0%) 0/3 (0%)
Mixed 0/3 (0%) 0/3 (0%) 1/3 (33%)
Chemotherapy
4 3/13 (23.1%) 1/13 (7.7%) 2/13 (15.4%)
4 11/27 (40.7%) 7/27 (25.9%) 2/27 (7.4%)
DM, distant metastasis; BR, brain metastasis; LRF, local regional failure.
FIGURE 2. Kaplan–Meier estimate of brain metastases as a
function of age. FFDM, freedom from distant metastasis.
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local/regional failure (3/24 versus 1/16), BM (8/24 versus
0/16), and DM (14/24 versus 0/16).
Acute Toxicity
Five patients developed grade 3 esophagitis. As part of
this study, iced carafate was recommended and given to the
patients before and after radiation. The theory was to use
hypothermia to reduce mucosal damage. This was given to
33 of the 40 patients per the treating physicians. Three of 33
patients (9%) receiving the hypothermia developed grade 3
esophagitis, compared with two of seven patients (29%) who
did not receive hypothermia. One patient who developed
grade 3 toxicity discontinued therapy at 48.6 Gy. One week
after discontinuing therapy, the patient was admitted with
fevers and was found to have had an aspiration pneumonia.
Unfortunately, after an extended hospitalization, this led to
the development of acute respiratory distress syndrome and
his subsequent death. This was scored a grade 5 toxicity,
secondary to treatment-related complications. A second pa-
tient developed a grade 5 event after completion of radiation
and 1 week after that third cycle of carboplatin/paclitaxel.
This patient developed chest pain and shortness of breath and
became tachycardiac. A CT scan of the thorax performed on
the day he died suggested a pulmonary embolus.
Late Toxicity
Nine patients died of intercurrent disease. Three pa-
tients died after an acute myocardial infarction. Three pa-
tients died related to progression of their chronic pulmonary
disease. One patient who developed colon cancer died related
to metastatic disease from colon cancer (biopsy proven). Two
patients died due to unspecified causes. One patient devel-
oped a secondary malignancy 7½ years after combined-
modality therapy localized in the trachea with the pathology
consistent with small cell carcinoma. This patient is currently
under treatment. One patient developed a second non-small
cell lung cancer after treatment for a T1N1 NSCLC and
developed contralateral disease 5 years and 10 months, which
was presumed to be a new primary cancer. She is currently
under treatment for this cancer.
DISCUSSION
This prospective phase II trial demonstrated the feasi-
bility of combining systemic doses of carboplatin and pacli-
taxel with thoracic radiotherapy in completely resected stage
II and IIIA NSCLC. The regimen seemed to be well-tolerated
with 92% of patients receiving the planned dose of radiother-
apy and 83% of patients receiving three or four cycles of
chemotherapy. There were two grade 5 events, one treatment
related and one cancer related. This feasibility is nearly
identical with the RTOG study 97-05. In comparison, only
58% of patients received three or more cycles of chemother-
apy (cisplatin-based doublet) on NCIC JBR.10. In this trial,
no patient received radiotherapy.12
The role of concurrent chemotherapy and radiotherapy
in this trial was initially designed to develop a better tolerated
combination therapy. This trial was a follow-up study from
the initial Lung Cancer Study Group reported by Keller et
al.24 that demonstrated a local control benefit but no survival
benefit from the addition of radiotherapy to the mediastinum
for patients with pathologic stage II and IIIA NSCLC. In this
follow-up study, the use of concurrent cisplatin and etoposide
chemotherapy administered concurrently with radiotherapy
was compared with radiotherapy alone in patients with patho-
logic stage II or IIIA NSCLC. They were treated to 50.4 Gy
in 28 fractions with a boost for an additional 10.8 Gy to areas
where there was evidence of extranodal spread. The 5-year
survival in the radiation and chemotherapy arm was 33%.
Compared with the current study, the 5-year survival was
44% using a new and better tolerated chemotherapy regimen
consisting of carboplatin and paclitaxel. There was a possi-
bility that patients were staged better, but none of the patients
in this study underwent positron emission tomography eval-
uation. They did undergo the same staging studies that were
required in the ECOG study. The patient population in the
current series appeared very high risk with two thirds of
patients having N2 disease and 15% with positive margins,
which makes the survival rates even more remarkable. In
addition, when one compares the results of the current study
with the RTOG study that was recently reported by Bradley
et al.25 (RTOG 97-05), our results are very similar. The
median OS was 56 months in the 88 patients treated with a
similar approach. Patients treated in both groups were differ-
ent in that the current series included patients with positive
margins and did not include patients who were node negative
(i.e., T3N0). In addition, there was a larger percentage with
pathologic N2 disease (60% versus 48%). In either case, the
local failure rates in both studies were very similar. RTOG
97-05 had a local failure rate of 15% as the component of the
first failure making these two studies better than any similar
study. If we compare the results with the International Adju-
vant Lung Cancer Trial group, their survival at 5 years was
the same at 44%, but they included early stage disease (36%
with stage I disease). These results beg the question of
FIGURE 3. Kaplan–Meier estimate of overall survival (OS)
as a function of histology.
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whether postoperative chemotherapy administered with con-
current radiation should be further explored in future trials.
An interesting component that was described in the
current study was described in the Patterns of Failure section.
Interestingly, patients older than 60 years of age had a lower
risk of developing BM compared with the younger patients.
There was a 50% risk of developing BM for patients
younger than 60 years of age. Although this was not signif-
icant on MVA, this finding has been described previously.26
Carolan et al.26 reported that age was the only factor among
gender, histology, stage, weight loss, and treatment to predict
first failure in the brain (25.6% younger than 60 years of age
and 16.4% when older than 60). It appears from this small
cohort of young patients that this is being driven by the
histology. Table 2 demonstrates that all patients in whom DM
or BM developed also had adenocarcinomas. Although with
improved survival and better local or distant control, it is not
surprising that we are seeing an increased incidence in the
amount of BM (i.e., sanctuary site). Some have suggested the
use of prophylactic cranial radiotherapy in the group of
patients with locally advanced disease.27
The use of adjuvant paclitaxel and carboplatin with
thoracic radiotherapy in patients with resected stage II and III
disease appears rather promising with survival rates better
than its historical control. With new and better tolerated
systemic therapies and the encouraging survival rates seen in
this trial, a randomized phase III trial is warranted in this
group of patients with selected N1 (i.e., hilar node involve-
ment) and N2 disease. Optimally, a three-arm trial should be
performed comparing chemotherapy alone with two combi-
nation radiotherapy and chemotherapy arms (administered
concurrently versus sequentially). Based on the subset anal-
ysis of the ANITA trial, a European-led phase III trial will be
asking this question for completely resected N2 patients after
sequential chemotherapy (C. Le Pechoux, personal, commu-
nication).
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